重組抗體
重組抗體，也稱為基因工程抗體，是指通過DNA重組技術將抗體相應的基因序列根據需要進行改造和重組，并構建在質粒上，再通過蛋白外源表達技術將構建好的質粒轉染/轉化入適合的宿主細胞表達獲得的抗體。換言之，重組抗體是通過將免疫特異性重鏈和輕鏈抗體克隆到高產的哺乳動物表達載體中而制成的。將得到的載體引入到表達宿主（如細菌、酵母或哺乳動物）中，用于生產高質量的功能性抗體。重組抗體很好的解決了動物源抗體引起的人體排斥反應，使得抗體實現人源化，使抗體的效能更為完善。
近年來，重組抗體的使用在治療和診斷中變得越來越廣泛。 與傳統抗體相比具有顯著優勢，重組抗體變得越來越受青睞。最重要的一點是重組抗體可以最大化人源化以解決不同物種之間的異質性。
重組抗體可分為五大類：嵌合抗體、人源化抗體、全人源化抗體、小分子抗體、雙特異性抗體。華美生物擁有近700種重組兔單克隆抗體，具有高純度、親和力強以及批次間偏差小等特點。
產品特色
華美生物可提供各種類型的重組抗體，包括全長抗體、scFv、Fab、sdAb、同種型/亞型和各種形式的 Fc 融合蛋白。
華美生物的重組抗體已在多個應用平臺驗證，包括 WB、IF、IHC、FC、IP、ELISA、GICA 和 Neutralising。
CD146 Antibody (CSB-RA013563A0HU)
Positive WB detected in A375 whole cell lysate. All lanes CD146 antibody at 0.6μg/mL.
GAPDH Antibody (CSB-RA009232A0HU)
Positive WB detected in U87 whole cell lysate, Mouse brain tissue. All lanes GAPDH antibody at 0.31μg/mL.
CD9 Antibody (CSB-RA004969A0HU)
Positive WB detected in U87 whole cell lysate. All lanes CD9 antibody at 0.55μg/mL.
CD31 Antibody (CSB-RA017767A0HU)
Positive WB detected in THP-1 whole cell lysate. All lanes CD31 antibody at 0.95μg/mL.
Histone H3.3 Antibody (CSB-RA010109A0HU)
Immunofluorescence staining of Hela cells with the antibody at 1:60, counter-stained with DAPI.
CD21 Antibody (CSB-RA005934A0HU)
Immunofluorescence staining of Raji cells with the antibody at 1:34, counter-stained with DAPI.
Histone H3.1 Antibody (CSB-RA010418A0HU)
Immunofluorescence staining of Hela cells with the antibody at 1:93, counter-stained with DAPI.
CD97 Antibody (CSB-RA004972A0HU)
Immunofluorescence staining of Hela cells with the antibody at 1:87.5, counter-stained with DAPI.
CD34 Antibody (CSB-RA004926A0HU)
IHC image of the antibody diluted at 1:100 and staining in paraffin-embedded human kidney tissue performed on a Leica BondTM system.
CD4 Antibody (CSB-RA004935A0HU)
IHC image of the antibody diluted at 1:100 and staining in paraffin-embedded human spleen tissue performed on a Leica BondTM system.
CD44 Antibody (CSB-RA004938A0HU)
IHC image of the antibody diluted at 1:100 and staining in paraffin-embedded human tonsil tissue performed on a Leica BondTM system.
CD21 Antibody (CSB-RA005934A0HU)
IHC image of the antibody diluted at 1:100 and staining in paraffin-embedded human lung cancer performed on a Leica BondTM system.
CD81 Antibody (CSB-RA004960A0HU)
Overlay histogram showing Jurkat cells stained with the antibody (red line) at 1:50. Control antibody (green line) was used under the same conditions. Acquisition of >10,000 events was performed.
CD99 Antibody (CSB-RA004973A0HU)
Overlay histogram showing Jurkat cells stained with the antibody (red line) at 1:50. Control antibody (green line) was used under the same conditions. Acquisition of >10,000 events was performed.
CD74 Antibody (CSB-RA004956A0HU)
Overlay histogram showing Raji cells stained with the antibody (red line) at 1:50. Control antibody (green line) was used under the same conditions. Acquisition of >10,000 events was performed.
CD163 Antibody (CSB-RA801238A0HU)
Overlay histogram showing Raw264.7 cells stained with the antibody (red line) at 1:50. Control antibody (green line) was used under the same conditions. Acquisition of >10,000 events was performed.
HDAC6 Antibody (CSB-RA010242A0HU)
Lane 1: Rabbit control IgG instead of CSB-RA010242A0HU in HepG2 whole cell lysate.
Lane 2: CSB-RA010242A0HU (3μg) + HepG2 whole cell lysate (500μg)
Lane 3: HepG2 whole cell lysate (20μg)
CDC5L Antibody (CSB-RA858712A0HU)
Lane 1: Rabbit control IgG instead of CSB-RA858712A0HU in Hela whole cell lysate.
Lane 2: CSB-RA858712A0HU (3μg) + Hela whole cell lysate (500μg)
Lane 3: Hela whole cell lysate (20μg)
BAK1 Antibody (CSB-RA624111A0HU)
Lane 1: Rabbit control IgG instead of CSB-RA624111A0HU in HEK293 whole cell lysate.
Lane 2: CSB-RA624111A0HU (3μg) + HEK293 whole cell lysate (500μg)
Lane 3: HEK293 whole cell lysate (20μg)
ATM Antibody (CSB-RA618770A0HU)
Lane 1: Rabbit control IgG instead of CSB-RA618770A0HU in PC3 whole cell lysate.
Lane 2: CSB-RA618770A0HU (3μg) + PC3 whole cell lysate (500μg)
Lane 3: PC3 whole cell lysate (20μg)
Immobilize various types of SARS proteins at concentration of 2μg/ml on solid substrate, then react with SARS-CoV-2-S Antibody at concentration of 100μg/ml, 10μg/ml and 1μg/ml. It shows the SARS-CoV-2-S Antibody (CSB-RA33245A0GMY) is specific for SARS-CoV-2-S1-RBD protein, without any cross-reactivity with HCoV-OC43, HCoV-229E.
Immobilize various types of SARS proteins at concentration of 2μg/ml on solid substrate, then react with SARS-CoV-2-N Antibody at concentration of 100μg/ml, 10μg/ml and 1μg/ml. It shows the SARS-CoV-2-N Antibody (CSB-RA33255A0GMY) is specific for SARS-CoV-2-N protein, without any cross-reactivity with NL63-CoV, HCoV-OC43, HCoV-229E or HCoV-HKU1.
In the Colloidal Gold Immunochromatography Assay detection system, the background of antibody (CSB-RA33255A1GMY) is clean, the detection limit can be as low as 125ng/mL (8.75ng/0.07mL), and the sensitivity is very good.
In the Colloidal Gold Immunochromatography Assay detection system, the background of antibody (CSB-RA33255A2GMY) is clean, the detection limit can be as low as 15.625ng/ml (1.09ng/0.07ml), and the sensitivity is very good
Binding signal of SARS-CoV-2-S1-RBD (CSB-YP3324GMY1) and ACE2 protein-HRP conjugate (CSB-MP866317HU) was inhibited by S Antibody (CSB-RA33245A1GMY) with the IC50 is 2.38 μg/Ml.
SARS-CoV-2 Spike RBD Nanobody (CSB-RA33245A2GMY)
This nanobody competitively prevented SARS-CoV-2-S1-RBD (CSB-YP3324GMY1) from binding to ACE2-HRP conjugate (CSB-MP866317HU). The inhibition efficacy of the SARS-CoV-2-S1-RBD/ACE2 binding was positively proportionally to the nanobody concentrations. It showed that the nanobody effectively inhibited the SARS-CoV-2-S1-RBD/ACE2 binding. And the IC50 of the nanobody is 0.1074 μg/mL.
產品列表
您可以在下述列表中尋找您所需要的產品，或直接在頂部搜索框中輸入您需要查找的靶點、產品名稱、貨號。有任何問題，請點擊此處在線咨詢。
| 產品名稱 | 貨號 | 規格 |
|---|---|---|
| S Antibody | CSB-RA33245A1GMY | 100ul/50ul |
| N Antibody | CSB-RA33255A1GMY | 100ul/50ul |
| N Antibody, FITC conjugated | CSB-RA33255C1GMY | 100ul/50ul |
| N Antibody, Biotin conjugated | CSB-RA33255D1GMY | 100ul/50ul |
| S Antibody, FITC conjugated | CSB-RA33245C1GMY | 100ul/50ul |
| HMGB1 Antibody | CSB-RA439052A0HU | 100μl/50μl |
| FLNA Antibody | CSB-RA548809A0HU | 100μl/50μl |
| SSTR2 Antibody | CSB-RA827375A0HU | 100μl/50μl |
| TPBG Antibody | CSB-RA669019A0HU | 100μl/50μl |
| INS Antibody | CSB-RA584163A0HU | 100μl/50μl |
| KDM1A Antibody | CSB-RA222329A0HU | 100μl/50μl |
| AURKA Antibody | CSB-RA223479A0HU | 100μl/50μl |
| ALAS1 Antibody | CSB-RA266893A0HU | 100μl/50μl |
| LDLR Antibody | CSB-RA575353A0HU | 100μl/50μl |
| PDGFRB Antibody | CSB-RA213932A0HU | 100μl/50μl |
| MET Antibody | CSB-RA983271A0HU | 100μl/50μl |
| SLC2A1 Antibody | CSB-RA297401A0HU | 100μl/50μl |
| CD8A Antibody | CSB-RA934881A0HU | 100μl/50μl |
| MDK Antibody | CSB-RA276759A0HU | 100μl/50μl |
| PRMT5 Antibody | CSB-RA176962A0HU | 100μl/50μl |
關于重組抗體
與傳統抗體相比，重組抗體的優勢具體如下：
- 更高的一致性和重復性
因為重組抗體是由一組獨特的基因發展而來的，所以抗體生產是可控且可靠的?？梢员苊怆s交瘤細胞制備中的一些問題，如基因丟失、基因突變和細胞株漂移等。這使得抗體的批次間差異非常小，從而為您提供高度可重復的結果。
- 更高的靈敏度和特異性
利用重組技術，更容易通過抗體工程提高抗體特異性和靈敏度。所需克隆的選擇過程發生在雜交瘤細胞和重組克隆階段，這使我們能夠選擇最優的抗體質量。
- 易于擴展
隨著抗體基因的分離，與傳統單克隆技術相比，抗體表達能夠以任何規模在更短的時間內進行。這意味著我們可以在數周而非數月內產生定制抗體。
- 無動物高通量生產
一旦分離出產生抗體的基因，就可以實現無動物體外生產。
